SCHEDULE 13D/A: Dogwood Therapeutics Converts $19.9 Million Debt to Preferred Stock with CK Life Sciences Subsidiaries

Dogwood Therapeutics, Inc. has converted approximately $19.9 million in outstanding debt and accrued interest owed to Conjoint Inc., a subsidiary of CK Life Sciences Int'l., (Holdings) Inc., into Series A-1 Non-Voting Convertible Preferred Stock.

Summary

• Dogwood Therapeutics, Inc. (formerly Virios Therapeutics, Inc.) filed an Amendment No. 1 to its Schedule 13D, detailing recent financial transactions with its significant investors.
• On March 12, 2025, Dogwood Therapeutics entered into a Debt Exchange and Cancellation Agreement with Conjoint Inc., an indirect, wholly-owned subsidiary of CK Life Sciences Int'l., (Holdings) Inc.
• Under this agreement, $19,926,891, representing the aggregate principal and accrued interest of previous loans from Conjoint Inc. to Dogwood Therapeutics, was deemed repaid and cancelled.
• In exchange for the debt cancellation, Dogwood Therapeutics issued 284.2638 shares of its Series A-1 Non-Voting Convertible Preferred Stock to Conjoint Inc., based on a price of $7.01 per underlying Common Stock share.
• Each share of Series A-1 Preferred Stock is convertible into 10,000 shares of Common Stock, subject to approval by Dogwood Therapeutics' stockholders and a beneficial ownership limitation of 19.99% of the outstanding Common Stock.
• Sealbond Limited, another indirect, wholly-owned subsidiary of CK Life Sciences, directly owns 211,383 shares of Dogwood Therapeutics' Common Stock, representing approximately 15.9% of the 1,332,178 shares outstanding as of March 12, 2025.
• Sealbond also holds 2,108.3854 shares of Series A Preferred Stock, convertible into 21,083,854 Common Stock shares, which is also subject to stockholder approval and the 19.99% beneficial ownership limitation.
• Conjoint Inc. does not directly own Common Stock but holds Series A-1 Preferred Stock convertible into 2,842,638 Common Stock shares, subject to the same conditions.
• A Joinder and Amendment No. 1 to Registration Rights Agreement was also executed on March 12, 2025, adding Conjoint Inc. as a party and including the shares of Common Stock issuable upon conversion of the Series A-1 Preferred Stock as 'Registrable Securities'.

Sentiment

Score: 6

Explanation: The filing reports a factual debt-to-equity conversion. While it reduces debt, it introduces potential future dilution and conversion contingencies. The sentiment is neutral to slightly positive due to debt reduction, but tempered by the potential for significant dilution and the need for shareholder approval for full conversion.

Positives

• Dogwood Therapeutics has successfully eliminated approximately $19.9 million in debt and accrued interest from its balance sheet, improving its financial health.
• The debt-to-equity conversion strengthens the company's capital structure by reducing liabilities and potentially improving its credit profile.
• The transaction solidifies the investment and ongoing commitment of CK Life Sciences and its subsidiaries in Dogwood Therapeutics, indicating continued support.

Negatives

• The conversion of both Series A and Series A-1 Preferred Stock into common stock is contingent upon stockholder approval, introducing uncertainty regarding the full realization of the equity conversion.
• Potential for significant dilution for existing common stockholders if the preferred shares are fully converted, as millions of new common shares could be issued.
• The beneficial ownership limitation of 19.99% restricts immediate full conversion, potentially delaying the full debt-to-equity conversion and the investor's ability to fully realize their equity stake.

Risks

• Conversion of Series A and Series A-1 Preferred Stock into Common Stock is contingent upon obtaining stockholder approval, which is not guaranteed.
• The beneficial ownership limitation of 19.99% restricts the immediate full conversion of preferred shares, potentially impacting the liquidity of these holdings or the full realization of the debt-to-equity conversion.
• Future potential dilution for existing common stockholders if the preferred shares are converted, as the number of outstanding common shares could increase substantially.
• The Reporting Persons may acquire additional shares or dispose of their holdings in the open market or privately, which could impact the company's stock price.
• The Reporting Persons may consider various alternative courses of action, including extraordinary corporate transactions (e.g., merger, reorganization, liquidation), sale of material assets, changes in the board or management, changes in capitalization or dividend policy, or actions affecting the company's listing or corporate structure.

Future Outlook

The Reporting Persons (Sealbond Limited, CK Life Sciences Int'l., (Holdings) Inc., and Conjoint Inc.) hold their investments in Dogwood Therapeutics for investment purposes. They may, in the ordinary course of business, acquire additional shares or dispose of their current holdings, subject to market conditions and their investment policies. They may also consider various alternative courses of action, including extraordinary corporate transactions, changes in the company's board or management, alterations to capitalization or dividend policy, or actions affecting the company's listing or corporate structure. However, no specific plans or proposals for such actions are currently in place, beyond ongoing discussions by directors who are also executives of CK Life Sciences, in their fiduciary capacities.

Management Comments

• Mr. Yu, who is the Deputy Chairman and an Executive Director of CK Life Sciences, and Dr. Toh, who is a Vice President, the Chief Scientific Officer and an Executive Director of CK Life Sciences, each of whom are members of the Company's board of directors, may from time to time discuss or consider plans or proposals in their respective fiduciary capacities as directors of the Company.

Industry Context

This filing reflects a common strategy in the biotechnology sector where early-stage companies, like Dogwood Therapeutics, often rely on debt financing from strategic investors or related parties. The subsequent conversion of debt to equity, particularly preferred stock, is a mechanism to strengthen the balance sheet by reducing liabilities while providing the investor with a pathway to equity ownership, albeit often with conversion contingencies like shareholder approval and beneficial ownership limitations. This type of transaction can be seen as a vote of confidence from a significant investor (CK Life Sciences) in the long-term prospects of Dogwood Therapeutics' biotechnology products, while also managing immediate cash flow needs for research and development.

Comparison to Industry Standards

• The conversion of debt into preferred stock is a common financial restructuring tool used by biotechnology companies, particularly those in development stages, to manage cash flow and reduce immediate debt obligations. This is comparable to similar transactions seen in the biotech industry where strategic investors or venture capital firms convert bridge loans or convertible notes into equity.
• The beneficial ownership limitation of 19.99% is a standard provision often included in such agreements to avoid triggering certain change of control provisions or shareholder approval thresholds under exchange rules (e.g., Nasdaq Listing Rules 5110 and 5635(b)) without explicit shareholder consent.
• The requirement for stockholder approval for conversion is also a standard governance practice for significant equity issuances that could lead to substantial dilution or a change in control.

Corporate Governance

Related Party Transactions

• The Debt Exchange and Cancellation Agreement was entered into between Dogwood Therapeutics, Inc. and Conjoint Inc., where Conjoint Inc. is an indirect, wholly-owned subsidiary of CK Life Sciences Int'l., (Holdings) Inc., a significant investor in Dogwood Therapeutics.
• Sealbond Limited, another indirect, wholly-owned subsidiary of CK Life Sciences Int'l., (Holdings) Inc., is also a Reporting Person and holds existing Common Stock and Series A Preferred Stock in Dogwood Therapeutics.
• The Joinder and Amendment No. 1 to Registration Rights Agreement was executed between Dogwood Therapeutics, Sealbond Limited, and Conjoint Inc., further solidifying the relationship between these related entities.

Stakeholder Impact

• Shareholders: Potential for significant dilution if the preferred shares are fully converted, as the number of outstanding common shares could increase substantially. However, the reduction of debt could improve the company's financial stability.
• Creditors: The conversion of debt to equity reduces the company's liabilities, potentially improving its credit profile.
• Management/Board: The Series A-1 Preferred Stock holders have protective voting rights over certain corporate actions, which could influence management decisions.

Next Steps

• Dogwood Therapeutics' stockholders need to approve the conversion of Series A and Series A-1 Preferred Stock into Common Stock.
• The Reporting Persons may, in the ordinary course of business, acquire additional shares or dispose of their current holdings.
• The Reporting Persons may consider various alternative corporate actions, including mergers, asset sales, changes in management or board, or changes in capitalization.

Key Dates

Keywords

Dogwood Therapeutics, SEC Filing, Schedule 13D, Debt Exchange, Preferred Stock, Convertible Securities, CK Life Sciences, Sealbond Limited, Conjoint Inc., Biotechnology, Financial Restructuring, Shareholder Approval, Beneficial Ownership, Dilution